Financhill
Sell
40

XLV Quote, Financials, Valuation and Earnings

Last price:
$131.43
Seasonality move :
1.73%
Day range:
$131.13 - $132.58
52-week range:
$127.35 - $159.64
Dividend yield:
1.78%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
11.1M
Avg. volume:
10.4M
1-year change:
-7.84%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
XLV
Health Care Select Sector SPDR Fund
-- -- -- -- --
FHLC
Fidelity MSCI Health Care Index ETF
-- -- -- -- --
PBE
Invesco Biotechnology & Genome ETF
-- -- -- -- --
PJP
Invesco Pharmaceuticals ETF
-- -- -- -- --
XBI
SPDR S&P Biotech ETF
-- -- -- -- --
XPH
SPDR S&P Pharmaceuticals ETF
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
XLV
Health Care Select Sector SPDR Fund
$131.48 -- -- -- $0.56 1.78% --
FHLC
Fidelity MSCI Health Care Index ETF
$62.10 -- -- -- $0.25 1.61% --
PBE
Invesco Biotechnology & Genome ETF
$62.62 -- -- -- $0.03 0.07% --
PJP
Invesco Pharmaceuticals ETF
$78.91 -- -- -- $0.27 1.15% --
XBI
SPDR S&P Biotech ETF
$78.77 -- -- -- $0.01 0.18% --
XPH
SPDR S&P Pharmaceuticals ETF
$40.12 -- -- -- $0.15 1.64% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
XLV
Health Care Select Sector SPDR Fund
-- 0.887 -- --
FHLC
Fidelity MSCI Health Care Index ETF
-- 0.959 -- --
PBE
Invesco Biotechnology & Genome ETF
-- 1.183 -- --
PJP
Invesco Pharmaceuticals ETF
-- 0.581 -- --
XBI
SPDR S&P Biotech ETF
-- 1.543 -- --
XPH
SPDR S&P Pharmaceuticals ETF
-- 0.578 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
XLV
Health Care Select Sector SPDR Fund
-- -- -- -- -- --
FHLC
Fidelity MSCI Health Care Index ETF
-- -- -- -- -- --
PBE
Invesco Biotechnology & Genome ETF
-- -- -- -- -- --
PJP
Invesco Pharmaceuticals ETF
-- -- -- -- -- --
XBI
SPDR S&P Biotech ETF
-- -- -- -- -- --
XPH
SPDR S&P Pharmaceuticals ETF
-- -- -- -- -- --

Health Care Select Sector SPDR Fund vs. Competitors

  • Which has Higher Returns XLV or FHLC?

    Fidelity MSCI Health Care Index ETF has a net margin of -- compared to Health Care Select Sector SPDR Fund's net margin of --. Health Care Select Sector SPDR Fund's return on equity of -- beat Fidelity MSCI Health Care Index ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XLV
    Health Care Select Sector SPDR Fund
    -- -- --
    FHLC
    Fidelity MSCI Health Care Index ETF
    -- -- --
  • What do Analysts Say About XLV or FHLC?

    Health Care Select Sector SPDR Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity MSCI Health Care Index ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Health Care Select Sector SPDR Fund has higher upside potential than Fidelity MSCI Health Care Index ETF, analysts believe Health Care Select Sector SPDR Fund is more attractive than Fidelity MSCI Health Care Index ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    XLV
    Health Care Select Sector SPDR Fund
    0 0 0
    FHLC
    Fidelity MSCI Health Care Index ETF
    0 0 0
  • Is XLV or FHLC More Risky?

    Health Care Select Sector SPDR Fund has a beta of 0.691, which suggesting that the stock is 30.908% less volatile than S&P 500. In comparison Fidelity MSCI Health Care Index ETF has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.843%.

  • Which is a Better Dividend Stock XLV or FHLC?

    Health Care Select Sector SPDR Fund has a quarterly dividend of $0.56 per share corresponding to a yield of 1.78%. Fidelity MSCI Health Care Index ETF offers a yield of 1.61% to investors and pays a quarterly dividend of $0.25 per share. Health Care Select Sector SPDR Fund pays -- of its earnings as a dividend. Fidelity MSCI Health Care Index ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XLV or FHLC?

    Health Care Select Sector SPDR Fund quarterly revenues are --, which are smaller than Fidelity MSCI Health Care Index ETF quarterly revenues of --. Health Care Select Sector SPDR Fund's net income of -- is lower than Fidelity MSCI Health Care Index ETF's net income of --. Notably, Health Care Select Sector SPDR Fund's price-to-earnings ratio is -- while Fidelity MSCI Health Care Index ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Health Care Select Sector SPDR Fund is -- versus -- for Fidelity MSCI Health Care Index ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XLV
    Health Care Select Sector SPDR Fund
    -- -- -- --
    FHLC
    Fidelity MSCI Health Care Index ETF
    -- -- -- --
  • Which has Higher Returns XLV or PBE?

    Invesco Biotechnology & Genome ETF has a net margin of -- compared to Health Care Select Sector SPDR Fund's net margin of --. Health Care Select Sector SPDR Fund's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XLV
    Health Care Select Sector SPDR Fund
    -- -- --
    PBE
    Invesco Biotechnology & Genome ETF
    -- -- --
  • What do Analysts Say About XLV or PBE?

    Health Care Select Sector SPDR Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Health Care Select Sector SPDR Fund has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Health Care Select Sector SPDR Fund is more attractive than Invesco Biotechnology & Genome ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    XLV
    Health Care Select Sector SPDR Fund
    0 0 0
    PBE
    Invesco Biotechnology & Genome ETF
    0 0 0
  • Is XLV or PBE More Risky?

    Health Care Select Sector SPDR Fund has a beta of 0.691, which suggesting that the stock is 30.908% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.840, suggesting its less volatile than the S&P 500 by 15.98%.

  • Which is a Better Dividend Stock XLV or PBE?

    Health Care Select Sector SPDR Fund has a quarterly dividend of $0.56 per share corresponding to a yield of 1.78%. Invesco Biotechnology & Genome ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. Health Care Select Sector SPDR Fund pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XLV or PBE?

    Health Care Select Sector SPDR Fund quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Health Care Select Sector SPDR Fund's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Health Care Select Sector SPDR Fund's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Health Care Select Sector SPDR Fund is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XLV
    Health Care Select Sector SPDR Fund
    -- -- -- --
    PBE
    Invesco Biotechnology & Genome ETF
    -- -- -- --
  • Which has Higher Returns XLV or PJP?

    Invesco Pharmaceuticals ETF has a net margin of -- compared to Health Care Select Sector SPDR Fund's net margin of --. Health Care Select Sector SPDR Fund's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XLV
    Health Care Select Sector SPDR Fund
    -- -- --
    PJP
    Invesco Pharmaceuticals ETF
    -- -- --
  • What do Analysts Say About XLV or PJP?

    Health Care Select Sector SPDR Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Health Care Select Sector SPDR Fund has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe Health Care Select Sector SPDR Fund is more attractive than Invesco Pharmaceuticals ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    XLV
    Health Care Select Sector SPDR Fund
    0 0 0
    PJP
    Invesco Pharmaceuticals ETF
    0 0 0
  • Is XLV or PJP More Risky?

    Health Care Select Sector SPDR Fund has a beta of 0.691, which suggesting that the stock is 30.908% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.530, suggesting its less volatile than the S&P 500 by 46.992%.

  • Which is a Better Dividend Stock XLV or PJP?

    Health Care Select Sector SPDR Fund has a quarterly dividend of $0.56 per share corresponding to a yield of 1.78%. Invesco Pharmaceuticals ETF offers a yield of 1.15% to investors and pays a quarterly dividend of $0.27 per share. Health Care Select Sector SPDR Fund pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XLV or PJP?

    Health Care Select Sector SPDR Fund quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. Health Care Select Sector SPDR Fund's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, Health Care Select Sector SPDR Fund's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Health Care Select Sector SPDR Fund is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XLV
    Health Care Select Sector SPDR Fund
    -- -- -- --
    PJP
    Invesco Pharmaceuticals ETF
    -- -- -- --
  • Which has Higher Returns XLV or XBI?

    SPDR S&P Biotech ETF has a net margin of -- compared to Health Care Select Sector SPDR Fund's net margin of --. Health Care Select Sector SPDR Fund's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XLV
    Health Care Select Sector SPDR Fund
    -- -- --
    XBI
    SPDR S&P Biotech ETF
    -- -- --
  • What do Analysts Say About XLV or XBI?

    Health Care Select Sector SPDR Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Health Care Select Sector SPDR Fund has higher upside potential than SPDR S&P Biotech ETF, analysts believe Health Care Select Sector SPDR Fund is more attractive than SPDR S&P Biotech ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    XLV
    Health Care Select Sector SPDR Fund
    0 0 0
    XBI
    SPDR S&P Biotech ETF
    0 0 0
  • Is XLV or XBI More Risky?

    Health Care Select Sector SPDR Fund has a beta of 0.691, which suggesting that the stock is 30.908% less volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.976, suggesting its less volatile than the S&P 500 by 2.396%.

  • Which is a Better Dividend Stock XLV or XBI?

    Health Care Select Sector SPDR Fund has a quarterly dividend of $0.56 per share corresponding to a yield of 1.78%. SPDR S&P Biotech ETF offers a yield of 0.18% to investors and pays a quarterly dividend of $0.01 per share. Health Care Select Sector SPDR Fund pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XLV or XBI?

    Health Care Select Sector SPDR Fund quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. Health Care Select Sector SPDR Fund's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, Health Care Select Sector SPDR Fund's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Health Care Select Sector SPDR Fund is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XLV
    Health Care Select Sector SPDR Fund
    -- -- -- --
    XBI
    SPDR S&P Biotech ETF
    -- -- -- --
  • Which has Higher Returns XLV or XPH?

    SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Health Care Select Sector SPDR Fund's net margin of --. Health Care Select Sector SPDR Fund's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XLV
    Health Care Select Sector SPDR Fund
    -- -- --
    XPH
    SPDR S&P Pharmaceuticals ETF
    -- -- --
  • What do Analysts Say About XLV or XPH?

    Health Care Select Sector SPDR Fund has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Health Care Select Sector SPDR Fund has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe Health Care Select Sector SPDR Fund is more attractive than SPDR S&P Pharmaceuticals ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    XLV
    Health Care Select Sector SPDR Fund
    0 0 0
    XPH
    SPDR S&P Pharmaceuticals ETF
    0 0 0
  • Is XLV or XPH More Risky?

    Health Care Select Sector SPDR Fund has a beta of 0.691, which suggesting that the stock is 30.908% less volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.443%.

  • Which is a Better Dividend Stock XLV or XPH?

    Health Care Select Sector SPDR Fund has a quarterly dividend of $0.56 per share corresponding to a yield of 1.78%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.64% to investors and pays a quarterly dividend of $0.15 per share. Health Care Select Sector SPDR Fund pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XLV or XPH?

    Health Care Select Sector SPDR Fund quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Health Care Select Sector SPDR Fund's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Health Care Select Sector SPDR Fund's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Health Care Select Sector SPDR Fund is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XLV
    Health Care Select Sector SPDR Fund
    -- -- -- --
    XPH
    SPDR S&P Pharmaceuticals ETF
    -- -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
70
AGFY alert for May 29

Agrify [AGFY] is down 8.64% over the past day.

Buy
100
BOX alert for May 29

Box [BOX] is down 0.84% over the past day.

Sell
22
OKTA alert for May 29

Okta [OKTA] is down 1.04% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock